Protease inhibitors

Details Protease inhibitors Protease inhibitors

A - Human Necessities

61

K

A61K 31/175 (2006.01) A61K 31/34 (2006.01) A61K 31/38 (2006.01) A61K 31/41 (2006.01) A61K 31/42 (2006.01) A61K 31/425 (2006.01) A61K 31/44 (2006.01) A61K 31/47 (2006.01) A61K 31/535 (2006.01) C07C 281/06 (2006.01) C07D 213/54 (2006.01) C07D 217/16 (2006.01) C07D 263/32 (2006.01) C07D 265/30 (2006.01) C07D 277/64 (2006.01) C07D 307/81 (2006.01) C07D 401/12 (2006.01) C07D 405/12 (2006.01) C07D 409/12 (2006.01) C07D 413/04 (2006.01) C07D 417/12 (2006.01) C07D 495/04 (2006.01)

Patent

CA 2332492

The present invention provides diacyl carbohydrazide compounds, and pharmaceutically acceptable salts, hydrates and solvates thereof, which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, novel intermediates of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease, comprising inhibiting said bone loss or excessive cartilage or matrix degradation by administering to a patient in need thereof a compound of the present invention.

Cette invention, qui a trait à des composés de diacyl carbohydrazide ainsi qu'à leurs sels acceptables du point de vue pharmaceutique, leurs hydrates et leurs solvates, inhibant les protéases, y compris la cathepsine K, concerne également des compositions pharmaceutiques renfermant ces composés, de nouveaux intermédiaires de ces composés et des méthodes de traitement de la déperdition osseuse ou de la détérioration excessive du cartilage ou de la matrice osseuse, l'ostéoporose notamment, de traitement de pathologies gingivales, notamment la gingivite et la parodontite, de l'arthrite, plus précisément l'arthrose et la polyarthrite rhumatoïde, de la maladie osseuse de Paget, de l'hypercalcémie de type malin et de la maladie métabolique des os. Ces méthodes consistent à administrer à un patient, chez lequel il est nécessaire d'inhiber une déperdition osseuse ou une détérioration excessive du cartilage ou de la matrice osseuse, un composé de cette invention.

Affiliated with

Also associated with

Rating

Protease inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Protease inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Protease inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1799778